Healthleap Raises $38M to Build AI That Flags At-Risk Patients

Healthleap has raised $38 million in combined seed and Series A funding for an artificial intelligence platform that scans hospital patient records overnight to flag people who may be suffering from conditions like malnutrition or delirium that often go undiagnosed, according to TechCrunch. The financing breaks down into an $8 million seed round co-led by Sequoia Capital and First Round Capital, plus a $30 million Series A led by Hummingbird Ventures. The company has not disclosed its valuation.

The startup is currently deployed in more than 50 hospitals, CEO and co-founder Josiah Meyer told TechCrunch.

What does Healthleap's AI actually do?

Healthleap plugs into a hospital's electronic health record system and uses language models to mine clinicians' written notes for details that rarely make it into structured data fields — things like poor appetite, recent weight loss, muscle loss, or trouble swallowing. That unstructured information is combined with structured data such as lab results, vital signs, and medications to generate a nightly risk score for each adult inpatient.

"A patient's chart holds two kinds of data. Labs, weights, and vital signs sit in structured fields, but the most telling signs sit in clinicians' written notes: poor appetite, recent weight loss, muscle loss, trouble swallowing," Josiah Meyer said, according to TechCrunch. "Our developing approach is extracting affirmative or negated mentions of these clinical concepts in an easily extensible and scalable way."

Meyer described the daily cycle to TechCrunch this way: "Each night, we analyze every adult inpatient's record: lab results, vital signs, weights, medications, diet orders, diagnoses, clinicians' notes, and more. Each morning, we write a risk score into the care team's existing workflow with a dashboard accessible that holds additional information about the patients' trends."

The company says the software does not diagnose patients — it only surfaces cases for clinicians to review more closely.

Which conditions is the platform built to catch?

Healthleap's screening currently covers malnutrition and delirium, two conditions clinicians and researchers say are frequently missed in hospital settings. Research cited by TechCrunch suggests 20% to 50% of hospital inpatients are malnourished, a gap that can slow recovery and complicate treatment.

The company has also built programs targeting aspiration pneumonia, pressure ulcers, and readmission risk tied to congestive heart failure. Those additional screens are still undergoing further clinical validation, Meyer said.

How did Healthleap get here?

• 2022: Jemima and Josiah Meyer found the company in South Africa, initially building a clinical nutrition tool for dietitians.
• Pivot: The siblings expand the product into a broader platform aimed at flagging hospital patients at risk of undiagnosed illness.
• Seed round: An $8 million round co-led by Sequoia Capital and First Round Capital.
• Series A: A $30 million round led by Hummingbird Ventures, bringing total disclosed funding to $38 million.
• October 7, 2026: TechCrunch reports the combined financing, with the company's platform already running in more than 50 hospitals.

Why did Sequoia, First Round and Hummingbird back a hospital screening tool?

TechCrunch's reporting does not quote the investors directly, but the structure of the deal — a well-known seed pairing in Sequoia and First Round followed by a larger Series A from Hummingbird — points to a startup that moved from an early nutrition-specific tool to a platform investors view as extensible across multiple hospital-acquired or missed-diagnosis conditions. The company's own roadmap, spanning malnutrition, delirium, aspiration pneumonia, pressure ulcers, and heart-failure readmissions, suggests the bet is on breadth as much as depth.

What to watch next

• Whether Healthleap publishes clinical validation data for aspiration pneumonia, pressure ulcers, and congestive heart failure readmission risk, the three programs still in development.
• Hospital system growth beyond the current 50-plus deployments, and whether larger health systems adopt the nightly risk-scoring workflow.
• Any disclosure of valuation or additional investors as the Series A closes and the company scales its engineering and clinical teams.
• How regulators and hospital compliance officers treat AI tools that flag but do not diagnose, a distinction Healthleap emphasizes in its own description of the product.

The company has not said when it expects to expand its hospital count or release outcome data tied to the newer risk models. TechCrunch's original report is available here.